US Capitol Capsule: Clearing FDA's Generics Backlog Answer To Drug Price Controversy?
This article was originally published in Scrip
Executive Summary
With the recent "chatter" about the FDA's backlog of generic drug applications – some of it triggered by Capitol Hill's concerns over recent extreme price hikes of older medicines – regulators want to set the record straight: the agency is doing just fine in its reviews of those products, and actually is ahead of schedule, contrary to some reports and popular belief, officials told an exclusive small group of reporters on Oct. 16.